Xenon
Also sold as: Xenon
Related Medications
These drugs share a pharmacologic classification but are NOT interchangeable. Listing here does not imply clinical equivalence. A physician must evaluate each drug individually for the patient's specific condition.
Classification: Radiopharmaceutical Activity (source: RxClass/NLM)
- strontiumRadiopharmaceutical ActivitySame Class
- ammoniaRadiopharmaceutical ActivitySame Class
- rubidiumRadiopharmaceutical ActivitySame Class
- thalliumRadiopharmaceutical ActivitySame Class
- indiumRadiopharmaceutical ActivitySame Class
- fluorodeoxyglucose f18Radiopharmaceutical ActivitySame Class
- flutemetamolRadiopharmaceutical ActivitySame Class
- iodide ionRadiopharmaceutical ActivitySame Class
- fluoride ionRadiopharmaceutical ActivitySame Class
- cholineRadiopharmaceutical ActivitySame Class
- ioflupaneRadiopharmaceutical ActivitySame Class
- technetiumRadiopharmaceutical ActivitySame Class
- ibritumomab tiuxetanRadiopharmaceutical ActivitySame Class
- albumin,iodinated i-131 serumRadiopharmaceutical ActivitySame Class
Insurance Coverage User-Reported
No community coverage data yet for xenon.
Coverage data submission coming soon.
Drug Information
Indications & Uses
INDICATIONS AND USAGE: Inhalation of Xenon Xe 133 Gas has proved valuable for the evaluation of pulmonary function and for imaging the lungs. It may also be applied to assessment of cerebral flow.
Dosage & Administration
DOSAGE AND ADMINISTRATION: Xenon Xe 133 Gas is administered by inhalation from closed respirator systems or spirometers. The suggested activity range employed for inhalation by the average adult patient (70 kg) is: Pulmonary function including imaging: 74-1110MBq (2-30mCi) in 3 liters of air. Cerebral blood flow: 370-1110MBq (10-30mCi) in 3 liters of air. The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. RADIATION DOSIMETRY The estimated absorbed radiation doses Method of Calculation: A Schema for Absorbed-Dose Calculation for Biologically Distributed Radionuclides, Supplement No. 1, MIRD pamphlet No. 1, J. Nucl. Med., p.7 (1968). to an average patient (70 kg) for pulmonary perfusion and cerebral blood flow studies from a maximum dose of 1110 MBq (30mCi) of Xenon Xe 133 in 3 liters of air are shown in Table 4. Table 4. Radiation Doses Effective Whole Half-Time Lungs 99% of activity is in lungs. Brain Body mGy/1110MBq (rads/30mCi) Pulmonary Perfusion 2 min. 2.5(0.25) 0.014(0.0014) 0.027(0.0027) Cerebral Blood Flow 5 min. 6.3(0.63) 0.035(0.0035) 0.068(0.0068)
Warnings & Precautions
WARNINGS: Xenon Xe 133 Gas delivery systems, i.e., respirators or spirometers, and associated tubing assemblies must be leakproof to avoid loss of radioactivity into the environs not specifically protected by exhaust systems. Xenon Xe 133 adheres to some plastics and rubber and should not be allowed to stand in tubing or respirator containers. The unrecognized loss of radioactivity from the dose for administration may render the study non-diagnostic. The vial stopper contains dry natural rubber latex and may cause allergic reactions in providers or patients who are sensitive to latex.
Side Effects (Adverse Reactions)
ADVERSE REACTIONS: Adverse reactions related to the use of this agent have not been reported to date.
Contraindications
CONTRAINDICATIONS: None known.
Verify with Primary Sources
Always verify clinical information with authoritative sources.
Medical Disclaimer: Information on this page is sourced from FDA-approved labeling data and is for educational reference only. It does not constitute medical advice. This information does not establish a provider-patient relationship. Always verify with current prescribing information and consult a licensed healthcare professional before any clinical decision. Read full disclaimer.
Data sourced from RxNorm (NLM/NIH), FDA Orange Book, OpenFDA, DailyMed. Last updated: 2026-03-02.